GCP
CRSP icon

Gill Capital Partners’s CRISPR Therapeutics CRSP Stock Holding History

Gill Capital Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$856 Buy
+18
New +$949 ﹤0.01% 612

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Gill Capital Partners's CRSP Position: Q1 2026 in Review

Gill Capital Partners opened a new position in CRISPR Therapeutics (CRSP) in Q1 2026: 18 shares worth $856. The stake represents ﹤0.01% of the portfolio and ranks #612 among its holdings.

488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Gill Capital Partners held 18 shares of CRISPR Therapeutics worth $856 as of Q1 2026.
  • CRISPR Therapeutics was a new Gill Capital Partners position in Q1 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Gill Capital Partners's portfolio in Q1 2026, its #612 holding.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Gill Capital Partners's 13F filing for Q1 2026, filed 13 Apr 2026.